Operating Lease, Right-of-Use Asset of Bolt Biotherapeutics, Inc. from 31 Dec 2020 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Bolt Biotherapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset in USD history and change rate from 31 Dec 2020 to 30 Sep 2025.
  • Bolt Biotherapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending 30 Sep 2025 was $19,881,000, a 19% increase year-over-year.
Source SEC data
View on sec.gov
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Change (%)

Bolt Biotherapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset (USD)

Period Value YoY Chg Change % Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $19,881,000 +$3,125,000 +19% 30 Sep 2025 10-Q 12 Nov 2025 2025 Q3
Q2 2025 $20,517,000 +$2,958,000 +17% 30 Jun 2025 10-Q 14 Aug 2025 2025 Q2
Q1 2025 $21,141,000 +$2,794,000 +15% 31 Mar 2025 10-Q 12 May 2025 2025 Q1
Q4 2024 $21,756,000 +$2,636,000 +14% 31 Dec 2024 10-Q 12 Nov 2025 2025 Q3
Q3 2024 $16,756,000 -$3,122,000 -16% 30 Sep 2024 10-Q 12 Nov 2024 2024 Q3
Q2 2024 $17,559,000 -$3,063,000 -15% 30 Jun 2024 10-Q 13 Aug 2024 2024 Q2
Q1 2024 $18,347,000 -$3,006,000 -14% 31 Mar 2024 10-Q 14 May 2024 2024 Q1
Q4 2023 $19,120,000 -$2,952,000 -13% 31 Dec 2023 10-K 24 Mar 2025 2024 FY
Q3 2023 $19,878,000 -$2,899,000 -13% 30 Sep 2023 10-Q 09 Nov 2023 2023 Q3
Q2 2023 $20,622,000 -$1,985,000 -8.8% 30 Jun 2023 10-Q 07 Aug 2023 2023 Q2
Q1 2023 $21,353,000 -$1,921,000 -8.3% 31 Mar 2023 10-Q 11 May 2023 2023 Q1
Q4 2022 $22,072,000 -$2,373,000 -9.7% 31 Dec 2022 10-K 21 Mar 2024 2023 FY
Q3 2022 $22,777,000 -$2,439,000 -9.7% 30 Sep 2022 10-Q 10 Nov 2022 2022 Q3
Q2 2022 $22,607,000 -$3,370,000 -13% 30 Jun 2022 10-Q 10 Aug 2022 2022 Q2
Q1 2022 $23,274,000 +$11,796,000 +103% 31 Mar 2022 10-Q 12 May 2022 2022 Q1
Q4 2021 $24,445,000 +$12,178,000 +99% 31 Dec 2021 10-K 29 Mar 2023 2022 FY
Q3 2021 $25,216,000 30 Sep 2021 10-Q 09 Nov 2021 2021 Q3
Q2 2021 $25,977,000 30 Jun 2021 10-Q 12 Aug 2021 2021 Q2
Q1 2021 $11,478,000 31 Mar 2021 10-Q 13 May 2021 2021 Q1
Q4 2020 $12,267,000 31 Dec 2020 10-K 30 Mar 2022 2021 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.